scispace - formally typeset
F

Fabienne Venet

Researcher at Claude Bernard University Lyon 1

Publications -  229
Citations -  9269

Fabienne Venet is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Septic shock & Sepsis. The author has an hindex of 40, co-authored 189 publications receiving 6831 citations. Previous affiliations of Fabienne Venet include Rhode Island Hospital & HCL Technologies.

Papers
More filters
Journal ArticleDOI

Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock

TL;DR: The present preliminary results show that mHLA-DR is an independent predictor of mortality in septic shock patients, and may help to stratify patients when designing a mediator-directed therapy in a time-dependent manner.
Journal ArticleDOI

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

TL;DR: Data suggest that PD-1 may not only be a dysfunctional marker/effector of macrophages/monocytes, but may also be a potential therapeutic target for designing measures to modulate the innate immune response, thereby preventing the detrimental effects of sepsis.
Journal ArticleDOI

Advances in the understanding and treatment of sepsis-induced immunosuppression

TL;DR: The reappraisal of sepsis pathophysiology has resulted in a novel approach to the design of clinical trials evaluating sepsi treatments, based on an evaluation of the immune status and biomarker-based stratification of patients.
Journal ArticleDOI

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity.

TL;DR: The authors reviewed the intricacies of COVID-19 pathophysiology, its various phenotypes, and the anti-SARS-CoV-2 host response at the humoral and cellular levels.
Journal ArticleDOI

Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.

TL;DR: This review focuses on immune dysfunctions described in septic patients and on their potential use as markers on a routine standardized basis for prediction of adverse outcome or of occurrence of secondary nosocomial infections.